Immunotherapy plus chemo for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) given with standard chemotherapy, compared to chemotherapy alone, for people with triple-negative breast cancer that has spread and hasn't been helped by earlier treatments. The goal is to see if adding this immunotherapy can shrink tumors or slow the cancer's growth better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have a type of breast cancer called triple-negative breast cancer, and it has either spread to other parts of your body or cannot be removed with surgery.
- You have had one or two previous treatments for advanced breast cancer, and the cancer has continued to grow despite these treatments.
- You have not taken certain immunotherapy drugs (like PD-1/PD-L1 or CTLA-4 inhibitors) before, or if you did, it wasn't recent and didn't cause severe side effects.
- You must be able to provide a small tissue sample (from a recent biopsy or an older stored sample) and blood samples for testing.
- Your overall health is good enough for chemotherapy, and you do not have serious heart, lung, or other medical problems that are not well controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
This study tests a combination of an immunotherapy drug (PD-L1 inhibitor) with a special low-dose chemotherapy regimen (VEX) plus optional radiation for advanced triple-negative breast cancer. The goal is to see if this approach works better than standard treatments.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests whether a short course of an immunotherapy drug (called sintilimab) combined with two standard chemotherapy drugs can shrink tumors before surgery in patients with triple-negative breast cancer. The goal is to see if this combination improves treatment response and outcomes.
This study tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy after surgery can help patients with aggressive triple-negative breast cancer that has spread to lymph nodes. The goal is to see if this combination prevents cancer from coming back.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
Hear when a new Triple Negative Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.